

Date: 12/02/2024

To, Listing Compliance Department BSE Limited Phiroze Jeejeebhoy Tower, 25<sup>th</sup> Floor Dalal Street, Mumbai – 400 001

Scrip Code: 538964

Respected Sir/Madam,

Subject: Unaudited Financial Results for the Quarter and Nine Months ended on December 31, 2023

We are pleased to forward herewith Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2023 along with limited review report of Auditor in compliance with the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The said financial results have been approved by Board of Directors at their meeting held on February 12, 2024.

We are also arranging to publish the same in newspaper in accordance with provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

FOR MERCURY LABORATORIES LIMITED

RAJENDRA SHAH MANAGING DIRECTOR DIN 00257253

Encl: As above



## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

(INR.in lakhs)

							(INR.in lakhs)
	Particulars	THREE MONTHS ENDED			NINE MONTHS ENDED		YEAR ENDED
Sr. No.		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.202
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITE
I	Revenue from Operations	1,711.47	2,275.51	1,623.10	5,819.18	5,590.24	7,533.3
II	Other Income	17.67	35.56	58.21	67.76	129.22	171.93
Ш	Total Revenue (I+II)	1,729.14	2,311.07	1,681.31	5,886.94	5,719.46	7,705.30
IV	Expenses						
	a. Cost of materials consumed	648.56	741.03	620.56	2,077.56	2,123.85	2,857.42
	b. Purchase of Stock in Trade	58.52	84.56	65.67	192.49	169.61	238.70
	c. Changes in inventories of finished goods, work in progress and stock in trade	21.99	124.55	(5.98)	130.83	(12.00)	(54.52
	d. Employee benefits expense	366.96	380.33	366.93	1,119.06	1,063.52	1,422.74
	e. Finance Costs	10.10	10.93	8.21	28.57	26.37	36.19
	f. Depreciation and Amortisation expenses	71.88	70.56	62.63	209.97	186.40	248.33
	g. Other Expenses	392.49	696.24	518.16	1,661.34	1,492.54	2,211.93
	Total Expenses(IV)	1,570.50	2,108.20	1,636.18	5,419.82	5,050.29	6,960.84
V	Profit before Tax ( III - IV)	158.64	202.87	45.13	467.12	669.17	744.40
VI	Tax Expenses						
	a ) Current Tax	50.55	64.00	0.00	149.55	181.00	225.2
	b ) Deferred Tax	(12.24)	(11.90)	(15.52)	(53.51)	(33.06)	(33.84
	c ) Income Tax relating to Earlier Years	(3.32)	-	-	(3.32)	-	(4.83
VII	Net Profit after Tax (V-VI)	123.65	150.77	60.65	374.40	521.23	557.8
VIII	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss remeasurement of the net defined benefit liability/ assets	1.11	(8.08)	-	8.59	-	21.82
	ii. Income tax relating to items that will not be reclassified to profit or loss	(0.28)	2.03	-	(9.73)	-	(5.49
	Total other comprehensive income, net of tax	0.83	(6.05)	-	(1.14)	-	16.33
IX	Total Comprehensive Income	124.48	144.72	60.65	373.26	521.23	574.21
	Paid up equity share capital	_	_	_	_	_	120.00
X	(face value of Rs.10/- each)						
XI	Other Equity	-	-	-	-	-	4,442.89
XII	Earning Per Share (EPS)*	10.55	10				
	a) Basic & Diluted	10.30	12.56	5.05	31.20	43.44	46.49
	b) Basic & Diluted	10.30	12.56	5.05	31.20	43.44	46.49

<sup>\*</sup> for the period only and not annualised

Place: Vadodara Date: 12/02/2024 By order of the Board of Directors Mercury Laboratories Limited

> Mr. Rajendra R Shah Managing Director DIN: 00257253

Head Office & Factory - 1 :

2/13-14, Gorwa Industrial Estate, Gorwa, Vadodara - 390 016, Ph. : 0265 2280180. E-mail : mllbrd@mercurylabs.com Factory - 2:

Halol-Vadodara Road, Vill. : Jarod, Vadodara - 391 510. Ph. : 02668 274312. Regd. Office :

1st Floor 18,Shreeji Bhuvan, 51, Mangaldas Road, Princess Street, Mumbai - 400 002. Ph.: 022 66372841. Fax: 022 2201 5441. E-mail: secretarial@mercurylabs.com

CIN NO.: L74239MH1982PLC026341

An ISO & WHO - GMP Certified

Website : www.mercurylabs.com



## **NOTES ON UNAUDITED FINANCIAL RESULTS:**

- 1. The above Financial results for the quarter and nine months ended on December 31,2023 were reviewed and recommended by the Audit Committee and thereafter approved by Board of Directors at their respective meetings held on February 12, 2024 at Vadodara.
- 2. The Statutory Auditors have performed a 'Limited Review' of the above financial results for the quarter and half year ended on December 31,2023.
- 3. The financial results of the Company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms with Regulation 33 of SEBI (LODR), 2015 and SEBI Circular dated 05.07.2016.
- 4. The business of the Company falls under Single Segment i.e. "Pharmaceuticals Products".
- 5. Previous quarter's figure has been re grouped / re classified, wherever necessary to confirm to current period classification.

Place: Vadodara Date: 12/02/2024

By order of the Board of Directors Mercury Laboratories Limited

Mr. Rajendra R Shah Managing Director DIN:00257253 Limited Review Report on the Unaudited Standalone Financial Results for the Quarter and Nine months ended December 31, 2023 pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015.

To, The Board of Directors, Mercury Laboratories Limited

- We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Mercury Laboratories Limited (the "Company") for the quarter and nine months ended December 31, 2023 (the "Statement"), being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
- 3 Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Naresh & Co.
Chartered Accountants
FRN: 106928W

CA Abhijeet Dandekar Partner

M. No. 108377

UDIN: 24108377BKB0PK7836

Place: Vadodara

Date: 12th February, 2024